Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.55 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.50 |
| ▸ | FABP4 | P15090 | 7/20 | 0.43 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | EIF4E | P06730 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | FABP3 | P05413 | 3/20 | 0.39 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4733527 | 0.88 | XDH (0.44) | PARP1BCAT2FABP4XDHSLC22A12 | |
| SCHEMBL4738771 | 0.84 | ACMSD (0.51) | PARP1FABP4XDHSLC22A12NPC1 | |
| SCHEMBL4738866 | 0.84 | MCL1 (0.51) | PARP1FABP4XDHSLC22A12FABP3 | |
| SCHEMBL4733757 | 0.82 | MCL1 (0.53) | PARP1FABP4XDHSLC22A12FABP3 | |
| SCHEMBL4785932 | 0.80 | ACMSD (0.49) | PARP1FABP4XDHSLC22A12FABP3 | |
| SCHEMBL4738907 | 0.78 | PARP1 (0.50) | PARP1FABP4XDHSLC22A12CYP11B2 | |
| SCHEMBL4735248 | 0.78 | DHODH (0.46) | PARP1FABP4XDHSLC22A12FABP3 | |
| SCHEMBL4733980 | 0.77 | PTGER2 (0.45) | XDHSLC22A12 | |
| SCHEMBL4736790 | 0.76 | MCL1 (0.52) | PARP1FABP4XDHSLC22A12FABP3 | |
| SCHEMBL4734718 | 0.76 | ACMSD (0.54) | PARP1FABP4XDHSLC22A12FABP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207728-A1 | BICYCLIC ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AG (DE) | 2008-08-28 | — | — | US | claimed |
| WO-2008071455-A1 | BICYCLIC ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-19 | — | — | WO | claimed |
| US-20080207728-A1 | BICYCLIC ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AG (DE) | 2008-08-28 | — | — | US | disclosed |
| WO-2008071455-A1 | BICYCLIC ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207728-A1 | BICYCLIC ACYLTRYPTOPHANOLS | FSHR, GNRHR, TPH1 | PARP1 1061/4885BCAT2 1099/4885FABP4 2397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.